Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cooperation of Musashi‐2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer

21 Feb 2017

Abstract excerpt

ABSTRACT Our earlier work showed that Musashi (MSI)‐2 promoted the development of pancreatic cancer (PC) by down‐regulating Numb, which prevented murine double‐minute (MDM)‐2–mediated p53 ubiquitin degradation. Thus, we investigate the relationship among MSI2, Numb, MDM2, and p53 in PC in vitro and in vivo , an association that has not been reported to our knowledge. MSI2 had no relationship with mutant p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation
Share to Hedgehog Signaling Pathway Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28223335
DOI: 10.1096/fj.201601240r

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cooperation of Musashi‐2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancerPMID 28223335Read ↗

Musashi2 promotes the progression of pancreatic cancer through a novel ISYNA1‐p21/ZEB‐1 pathwaySemantic proximity Read ↗

MSI2 regulates NLK-mediated EMT and PI3K/AKT/mTOR pathway to promote pancreatic cancer progressionSemantic proximity Read ↗

RNA binding protein Pumilio2 promotes chemoresistance of pancreatic cancer via focal adhesion pathway and interacting with transcription factor EGR1Semantic proximity Read ↗

The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer.Semantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancerSemantic proximity Read ↗

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer CellsSemantic proximity Read ↗

Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53‐independent pancreatic cancer cell deathSemantic proximity Read ↗

LncRNA-TUG1/EZH2 axis promotes cell proliferation, migration and the EMT phenotype formation through sponging miR-382Semantic proximity Read ↗

Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.Semantic proximity Read ↗

The homeobox gene <i>MSX2</i> determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene <i>ABCG2</i>Semantic proximity Read ↗

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.